Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Treprostinil Palmitil Inhalation Powder in Healthy Volunteers
NCT06091579Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Sep 2020
- Primary completion
- Jan 2021
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of treprostinil palmitil in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) (5 arms), sponsored by Insmed Incorporated. Primary endpoint: Number of Participants who Experienced an Adverse Event (AE). Started Sep 2020; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on NCT06091579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091579.